Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013

 Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart
                     Association Scientific Sessions 2013

First Long-Term Data of a PCSK9 Inhibitor to be Featured in Clinical Science:
Special Reports Session

PR Newswire

THOUSAND OAKS, Calif., Nov. 12, 2013

THOUSAND OAKS, Calif., Nov. 12, 2013 /PRNewswire/ --Amgen (NASDAQ: AMGN)
today announced that it will present new data on evolocumab (AMG 145), an
investigational fully human monoclonal antibody that inhibits PCSK9, a protein
that reduces the liver's ability to remove low-density lipoprotein cholesterol
(LDL-C), or "bad" cholesterol, from the blood^1, at the upcoming American
Heart Association (AHA) Scientific Sessions 2013, being held Nov. 16 – 20 in

Data from the Phase 2 OSLER (Open Label Study of Long TERm Evaluation Against
LDL-C Trial) study, which evaluates the safety, tolerability and sustained
efficacy of long-term administration of evolocumab and standard of care in
more than 1,100 patients with high cholesterol, will be featured during a
Clinical Science: Special Reports session on Tuesday, Nov. 19, at 4:51 p.m.

"The Phase 2 OSLER study provides the first long-term 52-week data for a PCSK9
inhibitor in diverse patient populations with high cholesterol," said Sean E.
Harper, M.D., executive vice president of Research and Development at Amgen.
"We hope the data we are accumulating from our Phase 3 clinical program for
evolocumab will help advance care for patients who struggle to control high
cholesterol and have an urgent unmet need."

Additionally, Amgen will highlight findings from long-term open-label data
accumulated from patients in GAUSS (Goal Achievement after Utilizing an
anti-PCSK9 antibody in Statin intolerant Subjects) and MENDEL (Monoclonal
Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently Not
Receiving Drug Therapy For Easing Lipid Levels), two Phase 2 studies that
evaluated evolocumab in patients with hyperlipidemia who cannot tolerate
statins and as a stand-alone treatment, respectively.

Data presented on evolocumab will include:

  oRandomized Comparison of the Safety, Tolerability, and Efficacy of
    Long-Term Administration of AMG 145 Versus Standard of Care in 1104
    Patients: 52-Week Results from the OSLER Study
    CS.03, Clinical Science: Special Reports, Tuesday, Nov. 19, 4:51 - 5:01
    p.m. CST (Ballrooms C1 & C2)
  oEfficacy and Safety of Long-Term Treatment with AMG 145 Monotherapy
    Abstract 12191, Abstract Poster Session, Tuesday, Nov. 19, 3 - 4:30 p.m.
    CST (Hall F, Core 2, Poster Board: 2010)
  oEfficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients
    With Statin Intolerance
    Abstract 12621, Abstract Poster Session, Tuesday, Nov. 19, 3 - 4:30 p.m.
    CST (Hall F, Core 2, Poster Board: 2009)

Amgen will also  host a webcast investor meeting at AHA on Tuesday, Nov. 19,
at 7 p.m. CST. Sean E. Harper, M.D., executive vice president of Research and
Development at Amgen, along with members of Amgen's clinical development team
and clinical investigators, will participate at the investor meeting to
discuss data being presented at AHA.

Live audio of the investor meeting will be simultaneously broadcast over the
Internet and will be available to members of the news media, investors and the
general public.

The webcast of the conference, as with other selected presentations regarding
developments in Amgen's business given by management at certain investor and
medical conferences, can be found on Amgen's website,, under
Investors. Information regarding presentation times, webcast availability and
webcast links are noted on Amgen's Investor Relations Events Calendar. The
webcast will be archived and available for replay for at least 90 days after
the event.

About Evolocumab (AMG 145)
Evolocumab is a fully human monoclonal antibody that inhibits proprotein
convertase subtilisin/kexin type 9 (PCSK9).^1 PCSK9 is a protein that targets
LDL receptors for degradation and thereby reduces the liver's ability to
remove LDL-C, or "bad" cholesterol, from the blood.^2 Evolocumab, being
developed by Amgen scientists, is designed to bind to PCSK9 and inhibit PCSK9
binding to LDL receptors on the liver's surface. In the absence of PCSK9,
there are more LDL receptors on the surface of the liver to remove LDL-C from
the blood.^1

Amgen has obtained the issuance of two U.S. patents related to evolocumab: USP
8,030,457 and USP 8,563,698. These patents will expire in 2029 but some
extension period may be available, subject to certain regulatory conditions
and statutory provisions for patent term extension. 

About PROFICIO: The Evolocumab Clinical Trial Program
PROFICIO, which stands for the Program to Reduce LDL-C and Cardiovascular
Outcomes Following Inhibition of PCSK9 In Different POpulations, is a large
and comprehensive clinical trial program evaluating evolocumab. ^ Phase 3
clinical trials for evolocumab are currently underway and build upon the Phase
2 studies.

The Phase 3 program includes 13 trials, with a combined planned enrollment of
more than 28,000 patients. The Phase 3 studies will evaluate evolocumab
administered every two weeks and monthly in multiple patient populations,
including in combination with statins in patients with hyperlipidemia
(LAPLACE-2), in patients with hyperlipidemia who cannot tolerate statins
(GAUSS-2), as a stand-alone treatment in patients with hyperlipidemia
(MENDEL-2), and in patients whose elevated cholesterol is caused by genetic
disorders called heterozygous (RUTHERFORD-2) and homozygous (TESLA and
TAUSSIG) familial hypercholesterolemia.

Five studies of evolocumab will provide long-term safety and efficacy data,
including the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9
Inhibition in Subjects with Elevated Risk) study, which will assess whether
treatment with evolocumab compared to placebo reduces recurrent cardiovascular
events in approximately 22,500 patients with cardiovascular disease.

Additional information about clinical trials of evolocumab can be found at

About Amgen
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.

For more information, visit and follow us on

Forward-Looking Statements
This news release contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission (SEC) reports filed
by Amgen, including Amgen's most recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's
most recent Forms 10-K, 10-Q and 8-K for additional information on the
uncertainties and risk factors related to our business. Unless otherwise
noted, Amgen is providing this information as of Nov. 12, 2013, and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans. The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for us to complete clinical trials and obtain regulatory approval for
product marketing has in the past varied and we expect similar variability in
the future. We develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates that are
derived from relationships may be subject to disputes between the parties or
may prove to be not as effective or as safe as we may have believed at the
time of entering into such relationship. Also, we or others could identify
safety, side effects or manufacturing problems with our products after they
are on the market. Our business may be impacted by government investigations,
litigation and products liability claims. We depend on third parties for a
significant portion of our manufacturing capacity for the supply of certain of
our current and future products and limits on supply may constrain sales of
certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies
imposed by third-party payors, including governments, private insurance plans
and managed care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward managed
care and healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. In addition, we compete with other companies with respect to
some of our marketed products as well as for the discovery and development of
new products. We believe that some of our newer products, product candidates
or new indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against products that
have lower prices, established reimbursement, superior performance, are easier
to administer, or that are otherwise competitive with our products. In
addition, while we routinely obtain patents for our products and technology,
the protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates. We cannot guarantee that we will be able to
produce commercially successful products or maintain the commercial success of
our existing products. Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of our
products or product candidates. Further, the discovery of significant problems
with a product similar to one of our products that implicate an entire class
of products could have a material adverse effect on sales of the affected
products and on our business and results of operations.

The scientific information discussed in this news release related to our
product candidates is preliminary and investigative. Such product candidates
are not approved by the U.S. Food and Drug Administration (FDA), and no
conclusions can or should be drawn regarding the safety or effectiveness of
the product candidates.

Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

1. Amgen Data on File, Investigator Brochure.
2. Abifadel M, et al. Mutations in PCSK9 cause autosomal dominant
hypercholesterolemia. Nat Genet 2003;34:154-156.



Press spacebar to pause and continue. Press esc to stop.